Logo

MYNZ

Mainz Biomed B.V.

MYNZ

Mainz Biomed B.V. • NASDAQ
$1.08 ▼ -3.57% (-0.04)
Market Cap $4.42 M
52w High $8.20
52w Low $0.18
Dividend Yield 0%
P/E -0.2
Volume 183.25K
Outstanding Shares 4.09M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $373.218K ▼ $9.144M ▼ $-10.627M ▲ -2.847K% ▼ $-7.71 ▲ $-10.087M ▼
Q2-2024 $520.773K ▲ $10.126M ▼ $-11.024M ▼ -2.117K% ▲ $-19.73 ▼ $-9.471M ▲
Q4-2023 $214.761K ▼ $13.901M ▲ $-5.183M ▲ -2.414K% ▲ $-11.73 ▼ $-12.611M ▼
Q2-2023 $500.208K ▲ $13.253M ▲ $-13.269M ▼ -2.653K% ▲ $-0.9 ▼ $-12.4M ▼
Q4-2022 $251.397K $12.452M $-12.575M -5.002K% $-0.87 $-11.877M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $6.236M ▲ $13.238M ▲ $7.192M ▼ $6.047M ▲
Q2-2024 $977.764K ▼ $8.454M ▼ $12.593M ▲ $-4.139M ▼
Q4-2023 $7.071M ▼ $15.409M ▼ $12.16M ▼ $3.249M ▼
Q2-2023 $10.911M ▼ $19.305M ▼ $14.128M ▲ $5.177M ▼
Q4-2022 $17.142M $20.241M $6.145M $14.096M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-10.627M ▲ $-8.945M ▼ $221.843K ▲ $14.048M ▲ $5.258M ▲ $-9.08M ▼
Q2-2024 $-11.024M ▼ $-8.145M ▼ $-420.66K ▼ $2.551M ▼ $977.764K ▲ $-8.265M ▼
Q4-2023 $-5.183M ▲ $-4.655M ▲ $-261.808K ▼ $3.466M ▼ $-2.249M ▼ $-4.917M ▲
Q2-2023 $-8.252M ▲ $-5.119M ▲ $-123.625K ▲ $5.419M ▲ $52.885K ▲ $-5.242M ▲
Q4-2022 $-13.785M $-8.313M $-406.037K $-148.233K $-26.007M $-8.719M

Five-Year Company Overview

Income Statement

Income Statement Income statement Mainz Biomed is still a pure development‑stage company. It has not generated product revenue over the last several years, so the income statement is driven almost entirely by research, clinical, and overhead spending. Losses are recurring but relatively modest in absolute terms, consistent with a small, early‑stage biotech focused on building out its technology and clinical programs rather than commercial sales. The large swings in earnings per share mainly reflect share count changes and the reverse split, not a sudden change in the underlying business. Overall, this is a classic pre‑revenue profile: costs to advance the science and clinical trials, with the hope of revenue only once regulatory approvals and broader commercialization are achieved.

Balance Sheet

Balance Sheet Balance sheet The balance sheet is very lean and small in scale. Assets are limited and heavily concentrated in cash, which is typical for a company whose main “assets” are its intellectual property, clinical data, and human capital rather than factories or equipment. Debt has been minimal, with only a brief period of borrowings, suggesting the company has mostly relied on equity funding to date. Shareholders’ equity has hovered around break‑even levels, reflecting ongoing losses and a very modest capital base. The reverse stock split significantly changed per‑share metrics but did not, by itself, strengthen the underlying financial resources. The main balance‑sheet questions are how long the current cash can support operations and how much additional funding will be needed to complete key trials and scale commercialization.

Cash Flow

Cash Flow Cash flow Cash flow is consistently negative from operations, which is expected for a pre‑revenue diagnostics company investing in R&D, clinical trials, and regulatory work. The company is using cash rather than generating it, so continued external financing is likely necessary over time. Free cash flow is also negative, but capital spending on physical assets appears minimal. Most cash outflow is tied to operating activities rather than big equipment or facilities, which fits their “asset‑light” model. The key risk is funding duration: without incoming revenue, the business depends on its ability to raise additional capital to sustain R&D, clinical programs, and eventual commercialization efforts.

Competitive Edge

Competitive Edge Competitive position Mainz Biomed is trying to carve out a position in cancer diagnostics, especially colorectal and pancreatic cancer, with non‑invasive tests that can be used at home or with simple sample collection. The main competitive angle is higher accuracy in detecting both cancers and pre‑cancerous lesions, which, if validated at scale, could differentiate it from existing options. The company’s partnership with a major U.S. diagnostics provider offers a potential fast track to distribution and trial execution in the United States, which is critical in this market. Its European “asset‑light” approach via local labs helps extend reach without heavy infrastructure spending. However, the competitive landscape is intense, with large, well‑funded players already established in colorectal screening and many emerging efforts in blood‑based cancer tests. Mainz Biomed’s position will ultimately depend on clinical data quality, regulatory outcomes, payer coverage, and how its tests perform in real‑world adoption against entrenched alternatives.

Innovation and R&D

Innovation and R&D Innovation & R&D Innovation is the core of Mainz Biomed’s story. The company is building its platform around proprietary mRNA biomarkers, PCR‑based testing, and AI‑driven algorithms to interpret complex molecular signals from simple stool or blood samples. Its lead product, ColoAlert, targets colorectal cancer screening with a strong emphasis on detecting pre‑cancerous polyps, aiming not only to find cancer but to prevent it. The next‑generation version, supported by ongoing and planned clinical trials, is meant to raise accuracy further and support a major U.S. push. PancAlert, focused on early pancreatic cancer detection, extends this platform into an area with very high unmet need and limited effective screening today. Early feasibility data appear encouraging, but they remain preliminary and will need to be confirmed in larger, more rigorous studies. Overall, the company is R&D‑heavy with clear scientific direction, but also high scientific, clinical, and regulatory uncertainty typical of novel diagnostics.

Summary

Summary Mainz Biomed is a high‑risk, early‑stage molecular diagnostics company with compelling scientific ambitions but a very fragile financial profile. It has no revenue yet, runs recurring operating losses, and depends on external financing to fund R&D and clinical trials. The balance sheet is light and dominated by cash, with little tangible asset backing and limited debt, which keeps financial leverage low but also highlights the reliance on future capital raises. Cash burn is ongoing, and the main financial question is whether it can sustain its programs long enough to achieve key catalysts. On the strategic side, the company is aiming to differentiate through better detection of pre‑cancerous lesions, proprietary biomarker panels, and AI‑supported interpretation, supported by partnerships with established diagnostic players and an “asset‑light” lab model. Future outcomes will hinge on clinical trial results, regulatory approvals, payer acceptance, and real‑world adoption, especially in the U.S. The opportunity in early cancer detection is large, but the path is long, data‑dependent, and capital‑intensive, with significant uncertainty along the way.

NEWS

November 18, 2025 · 8:01 AM UTC

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

Read more

November 12, 2025 · 8:01 AM UTC

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

Read more

November 10, 2025 · 8:01 AM UTC

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Read more

October 8, 2025 · 9:00 AM UTC

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Read more

September 2, 2025 · 8:01 AM UTC

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

Read more